Novartis has filed a patent for a method to treat B-cell lymphoma by combining CD 19 CAR therapy with a BCL2 inhibitor. The therapy targets MYC gene and anti-apoptotic gene activity. GlobalData’s report on Novartis gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Novartis AG - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Novartis, Cancer treatment biomarkers was a key innovation area identified from patents. Novartis's grant share as of January 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.

Combination therapy for b-cell lymphoma with cd19 car and bcl2 inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: Novartis AG

The patent application (Publication Number: US20240033358A1) describes a method for treating B-cell lymphoma in a subject with increased levels of MYC gene or anti-apoptotic gene by administering a therapy involving immune effector cells expressing a Chimeric Antigen Receptor (CAR) that binds to CD19 along with a BCL2 inhibitor. This combination therapy aims to effectively treat B-cell lymphoma in subjects who may not have responded adequately to CD19 CAR therapy alone.

Furthermore, the patent application details methods for treating relapsed or refractory B-cell lymphoma by administering a BCL2 inhibitor to subjects who have not responded well to CD19 CAR therapy. The application also outlines specific criteria for identifying subjects with MYC-positive lymphomas and the use of BCL2 inhibitors in combination with CD19 CAR therapy. The disclosed methods cover various types of B-cell lymphomas, including high-grade B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma, providing a comprehensive approach to treating these conditions. Additionally, the patent application emphasizes the importance of evaluating subjects for genetic alterations before and during treatment to optimize therapeutic outcomes.

To know more about GlobalData’s detailed insights on Novartis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies